Tempus AI, Inc. (NASDAQ: TEM) has a bullish thesis supported by strong financials. The company trades at $64.57 with a trailing P/E of 41.53. Morgan Stanley raised GE HealthCare’s target to $80 due to strong orders. Tempus operates in precision medicine, holding one of the largest multimodal datasets. Recent acquisitions have expanded capabilities, leading to improved margins and positive Adjusted EBITDA in Q3 2025. While GAAP profitability is negative, the company’s cash-generating business and innovative approach position it for significant growth. Overall, TEM offers a compelling opportunity for investors in the healthcare digitization and AI space.

Read more at Yahoo Finance: Tempus AI, Inc. (TEM): A Bull Case Theory